Cyproheptadine structure
|
Common Name | Cyproheptadine | ||
|---|---|---|---|---|
| CAS Number | 129-03-3 | Molecular Weight | 323.85900 | |
| Density | 1.115g/cm3 | Boiling Point | 440.1ºC at 760mmHg | |
| Molecular Formula | C21H22ClN | Melting Point | 298 °C (dec.)(lit.) | |
| MSDS | N/A | Flash Point | 194.5ºC | |
Use of CyproheptadineCyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders[1][2]. |
| Name | cyproheptadine |
|---|---|
| Synonym | More Synonyms |
| Description | Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Cyproheptadine (0.01-100 nM; 1 minute) dose-dependently inhibits serotonin-enhanced ADP-induced mouse platelet aggregation in vitro[2]. Cyproheptadine (10 nM) has the ability to inhibit 15 µM serotonin-enhanced ADP-induced (1 µM) tyrosine phosphorylation in platelets in vitro[2]. Cyproheptadine inhibits human platelet PS exposure (Annexin V), P-selectin, and GPIIb-IIIa (PAC-1 binding) activation in vitro[2]. |
| In Vivo | Cyproheptadine (1 mg/kg; i.p.; daily, for 5 days; C57BL/6 mice) exerts thromboprotective properties in vivo[2]. Animal Model: C57BL/6 mice (8-10 weeks old)[2] Dosage: 1 mg/kg Administration: Intraperitoneal injection; daily, for 5 days Result: Prolonged occlusion times and tail bleeding times in mice. |
| References |
[1]. Calka O, et, al. Effect of cyproheptadine on serum leptin levels. Adv Ther, 2005. 22(5): p. 424-8. |
| Density | 1.115g/cm3 |
|---|---|
| Boiling Point | 440.1ºC at 760mmHg |
| Melting Point | 298 °C (dec.)(lit.) |
| Molecular Formula | C21H22ClN |
| Molecular Weight | 323.85900 |
| Flash Point | 194.5ºC |
| Exact Mass | 323.14400 |
| PSA | 3.24000 |
| LogP | 5.43780 |
| Vapour Pressure | 6.03E-08mmHg at 25°C |
| Index of Refraction | 1.5339 (20ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Packaging Group | I; II; III |
|---|---|
| HS Code | 29143900 |
|
~99%
Cyproheptadine CAS#:129-03-3 |
| Literature: Hatano, Manabu; Ito, Orie; Suzuki, Shinji; Ishihara, Kazuaki Journal of Organic Chemistry, 2010 , vol. 75, # 15 p. 5008 - 5016 |
|
~%
Cyproheptadine CAS#:129-03-3 |
| Literature: Archiv der Pharmazie, , vol. 329, # 2 p. 87 - 94 |
|
~%
Cyproheptadine CAS#:129-03-3 |
| Literature: Tetrahedron, , vol. 44, # 19 p. 6197 - 6200 |
|
~%
Cyproheptadine CAS#:129-03-3 |
| Literature: Tetrahedron, , vol. 44, # 19 p. 6197 - 6200 |
|
~%
Cyproheptadine CAS#:129-03-3 |
| Literature: Archiv der Pharmazie, , vol. 329, # 2 p. 87 - 94 |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| cyproheptadiene |
| EINECS 204-928-9 |
| Dronactin |
| Periactine |
| Periactinol |
| MFCD00242817 |
| Eiproheptadine |
| Cyproheptadine |
| 1-methyl-4-(5-dibenzo[a,e]cycloheptatrienylidene)piperidine |
| MK 141 |
| 4-(5H-Dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine |
| Periactin |
| Cypoheptadine |
| 4-dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine |
| Periactin(R) |